Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | PPARG | P37231 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | AGTR2 | P50052 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 9/20 | 0.70 |
| ▸ | THRA | P10827 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | TTR | P02766 | 2/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.70 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.70 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.70 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Reverse Triiodothyronine SCHEMBL29354492 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL429433 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL93386 | 1.00 | MEN1 (1.00) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reverse Triiodothyronine SCHEMBL2317251 | 0.99 | MEN1 (0.97) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL30812344 | 0.93 | MEN1 (0.86) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Reversetriiodothyronine SCHEMBL30096343 | 0.92 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14576176 | 0.91 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14576177 | 0.91 | MEN1 (0.84) | MEN1KMT2APPARGNR1I2AGTR2 | |
| SCHEMBL14587190 | 0.90 | MEN1 (0.82) | MEN1KMT2APPARGNR1I2AGTR2 | |
| Rathyronine SCHEMBL10592340 | 0.88 | THRB (0.78) | MEN1KMT2APPARGNR1I2AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 661 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4733383-A1 | CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME | Japan Institute for Health Security (JP) | 2026-04-29 | — | — | EP | claimed |
| US-20260097100-A1 | CANCER TREATMENT BY INDUCTION OF TUMOR AND STEM CELL DIFFERENTIATION | LATHAM KEITH ROGER (US) | 2026-04-09 | — | — | US | claimed |
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2026-02-19 | — | — | US | claimed |
| WO-2024262610-A1 | CULTURE MEDIUM AND BLOOD CELL CLONE, AND METHOD FOR PRODUCING SAME | 国立研究開発法人国立国際医療研究センター | 2024-12-26 | — | — | WO | claimed |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| CN-116410922-A | Method for separating and differentiating animal fat source mesenchymal precursor cells | 浙江大学 | 2023-07-11 | — | — | CN | claimed |
| US-20200222348-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2020-07-16 | — | — | US | claimed |
| EP-3621602-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | Musli Thyropeutics Ltd. (IL) | 2020-03-18 | — | — | EP | claimed |
| WO-2018207171-A1 | BIMODAL MODIFIED RELEASE COMPOSITIONS FOR CANCER TREATMENT | MUSLI THYROPEUTICS LTD. (IL) | 2018-11-15 | — | — | WO | claimed |
| US-9526701-B2 | Sustained drug release and improved product stability using non-covalent particle coating methods | JEROME STEVENS PHARMACEUTICALS, INC. | 2016-12-27 | — | — | US | claimed |
| US-6221911-B1 | REDUCING SUBCUTANEOUS FAT DEPOSITS IN A SUBJECT; IMPROVING THE SKIN CONDITION OF A SUBJECT | KARO BIO AB (SE) | 2001-04-24 | — | — | US | claimed |
| EP-0742714-B1 | LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING THYROID HORMONES | KNOLL AG (DE) | 2001-03-28 | — | — | EP | claimed |
| EP-0751769-A4 | MEDICAL TREATMENT USING THYROID HORMONES | UNIV MICHIGAN (US) | 1998-05-27 | — | — | EP | claimed |
| US-5753254-A | INCLUDES DISINTEGRATING AGENT, FLAVORING AGENT, AND LUBRICATING AGENT | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-05-19 | — | — | US | claimed |
| EP-0751769-A1 | MEDICAL TREATMENT USING THYROID HORMONES | The Regents of The University of Michigan (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1995000135-A1 | MEDICAL TREATMENT USING THYROID HORMONES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 1995-01-05 | — | — | WO | claimed |
| EP-0163122-B1 | METHOD FOR THE DETERMINATION OF FREE SUBSTANCES IN BIOLOGICAL FLUIDS | Henning Berlin GmbH Chemie- und Pharmawerk (DE) | 1992-03-04 | — | — | EP | claimed |
| EP-0467466-A1 | Method for the purification of immunoreactive labeled thyroxine conjugates | EASTMAN KODAK COMPANY (US) | 1992-01-22 | — | — | EP | claimed |
| EP-0093653-B1 | PROCESS FOR THE PREPARATION OF IODO-THYRONINES AND IODO-THYROACETIC ACIDS BY ELECTROCHEMICAL REDUCTION AT A CONTROLLED POTENTIAL | SPIRAL Société à responsabilité limitée dite : (FR) | 1985-07-10 | — | — | EP | claimed |
| US-4490221-A | Process for preparing iodothyronines and iodothyroacetic acids by electrochemical reduction at controlled potential | SPIRAL SOCIETE A RESPONSABILITE LIMITEE DITE (FR) | 1984-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049178-A1 | CROSSLINKING AGENTS AND MEDICAL HYDROGELS FORMED THEREFROM | NPPA, MACF1, IGF1R | MEN1 1139/4885KMT2A 774/4885PPARG 2055/4885 |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | MEN1 4231/4885KMT2A 4248/4885PPARG 1073/4885 |
| US-20260097100-A1 | CANCER TREATMENT BY INDUCTION OF TUMOR AND STEM CELL DIFFERENTIATION | TPO, TSHR, THRB | MEN1 2848/4885KMT2A 4147/4885PPARG 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.